# SUMMARY OF PRODUCT CHARACTERISTICS

#### 1. Name of The Medicinal Product

1.1 Product Name : DEXANTA

1.2 Strength

Each chewable tablet contains:

Aluminium hydroxide dried gel equivalent to aluminium hydroxide 200 mg

Magnesium hydroxide 200 mg

Simethicone 50 mg

1.3 Pharmaceutical Dosage Form : Chewable tablet

## 2. Quality and Quantitative Composition

#### 2.1. Qualitative Declaration

Aluminium hydroxide dried gel equivalent to aluminium hydroxide

Magnesium hydroxide

Simethicone

#### 2.2. Quantitative Declaration

Aluminium hydroxide dried gel equivalent to aluminium hydroxide 200 mg

Magnesium hydroxide 200 mg

Simethicone 50 mg

## 3. Pharmaceutical Form

Chewable tablet.

Green, round and flat beveled edge tablet, diameter 13 mm, peppermint odor, sweet astringent taste. Side I marked DEXA, side II with breakline.

## 4. Clinical Particulars

### 4.1 Therapeutic Indications

Symptomatic relief of hyperacidity, gastritis, gastric ulcers, and duodenal ulcers such as nausea, gastric pain, heartburn, flatulence, and fullness of the stomach.

#### 4.2 Posology and Method of Administration

#### Adults

1 - 2 tablets, 3 - 4 times daily.

### Children 6-12 years

 $\frac{1}{2}$  – 1 tablet, 3 – 4 times daily.

#### 4.3 Contraindications

Should not be used in patients with severe impaired renal function.

## 4.4 Special Warning and Precautions for Use

- Should not be used continuously for more than 2 weeks, unless directed by a physician.
- Should not be used in children under 6 years, unless directed by a physician.
- Should be used with caution for long-term therapy and in patients with lowphosphorus diet since it may reduce the blood phosphorus levels

- 4.5 Interaction with Other Medicinal Products and Other Forms of Interactions
  DEXANTA may interact with certain drugs. Take DEXANTA at least 1–2 hours before
  or after other antiulcer drugs such as cimetidine or tetracycline antibiotic
- 4.6 Fertility, Pregnancy and Lactation Not applicable.
- 4.7 Effects on Ability to Drive and Use Machines: Not applicable.

#### 4.8 Undesirable Effects

Constipation, diarrhea, nausea, vomiting. These symptoms will disappear when the drug is discontinued

#### 4.9 Overdose

Large doses and prolonged use of this medicine may cause anorexia, malaise, muscle weakness, kidney stones, osteoporosis, hypotension, nausea, and vomiting. In case of overdose, get medical help or contact a physician.

## 5. Pharmacological Properties

5.1. Pharmacodynamic Properties

Aluminium hydroxide and magnesium hydroxide combination are an antacid to neutralize stomach acid and decrease pepsin activity thus relieving upper stomach pain and discomfort. Otherwise, this combination may offer the advantage of balancing the constipating and the laxative qualities. Simethicone releases the gas trapped in the gastrointestinal tract and relieves from bloating.

5.2. Pharmacokinetic Properties Not applicable.

5.3. Preclinical Safety Data Not applicable.

## 6. Pharmaceutical Particulars

6.1 List of Excipients:

Lactose, corn/maize starch, methylparaben, propylparaben, sodium cyclamate, saccharin sodium, eurocert tartrazine, FD&C blue no. 1 powder, peppermint flavor, talc, magnesium stearate, purified water

6.2 Incompatibilities:

Not applicable.

6.3 Shelf-life:

48 months

6.4 Special Precautions for Storage:

Store at temperatures below 30°C, protect from light.

6.5 Nature and Contents of Container:

Box, 10 catch covers x 1 strip x 10 chewable tablets.

6.6 Special Precautions for Disposal of a Used Medicinal Product or Waste Materials Derived from Such Medicinal Product and Other Handling of the Product: Not applicable.

# 7. Applicant / Holder of Certificate of Product Registration: Glorious Dexa Mandaya Ltd.

2nd Floor NIS Building, Plot B, Block H, Elephant Cement Way, Central Business District (CBD) Ikeja, Lagos, Nigeria

# 8. Drug Product Manufacturer:

Manufactured by:

## PT Beta Pharmacon

Kawasan Industri Suryacipta, Jl. Surya Madya Kav I-18C, Karawang-Indonesia

For:

## **PT Dexa Medica**

Jl. Jend. Bambang Utoyo No. 138 Palembang-Indonesia

## 9. Date of Revision of the Text:

November 14, 2023